Literature DB >> 17250816

Toll-like receptor (TLR) 2-9 agonists-induced cytokines and chemokines: I. Comparison with T cell receptor-induced responses.

Tarun K Ghosh1, Dan J Mickelson, Jason Fink, Jonathan C Solberg, Jon R Inglefield, Derek Hook, Shalley K Gupta, Sheila Gibson, Sefik S Alkan.   

Abstract

The cells of innate and adaptive immunity, although activated by different ligands, engage in cross talk to ensure a successful immune outcome. To better understand this interaction, we examined the demographic picture of individual TLR (TLRs 2-9) -driven profiles of eleven cytokines (IFN-alpha/beta, IFN-gamma, IL-12p40/IL-12p70, IL-4, 1L-13, TNF-alpha, IL-1beta, IL-2, IL-10) and four chemokines (MCP-1, MIP1beta, IL-8, and RANTES), and compared them with direct T-cell receptor triggered responses in an assay platform using human PBMCs. We find that T-cell activation by a combination of anti-CD3/anti-CD28/PHA induced a dominant IL-2, IL-13, and Type-II interferon (IFN-gamma) response without major IL-12 and little Type-I interferon (IFN-alphabeta) release. In contrast, TLR7 and TLR9 agonists induced high levels of Type-I interferons. The highest IFN-gamma levels were displayed by TLR8 and TLR7/8 agonists, which also induced the highest levels of pro-inflammatory cytokines IL-12, TNF-alpha, and IL-1beta. Amongst endosomal TLRs, TLR7 displayed a unique profile producing weak IL-12, IFN-gamma, TNF-alpha, IL-1beta, and IL-8. TLR7 and TLR9 resembled each other in their cytokine profile but differed in MIP-1beta and MCP1 chemokine profiles. Gram positive (TLR2, TLR2/6) and gram negative (TLR4) pathogen-derived TLR agonists displayed significant similarities in profile, but not in potency. TLR5 and TLR2/6 agonists paralleled TLR2 and TLR4 in generating pro-inflammatory chemokines MCP-1, MIP-1beta, RANTES, and IL-8 but yielded weak TNF-alpha and IL-1 responses. Taken together, the data show that diverse TLR agonists, despite their operation through common pathways induce distinct cytokine/chemokine profiles that in turn have little or no overlap with TCR-mediated response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17250816     DOI: 10.1016/j.cellimm.2006.12.002

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  46 in total

1.  TLR5, a novel and unidentified inflammatory mediator in rheumatoid arthritis that correlates with disease activity score and joint TNF-α levels.

Authors:  Nathan D Chamberlain; Olga M Vila; Michael V Volin; Suncica Volkov; Richard M Pope; William Swedler; Arthur M Mandelin; Shiva Shahrara
Journal:  J Immunol       Date:  2012-06-01       Impact factor: 5.422

2.  Mechanistic role of microRNA-146a in endotoxin-induced differential cross-regulation of TLR signaling.

Authors:  Md A Nahid; Minoru Satoh; Edward K L Chan
Journal:  J Immunol       Date:  2010-12-22       Impact factor: 5.422

Review 3.  Use of defined TLR ligands as adjuvants within human vaccines.

Authors:  Malcolm S Duthie; Hillarie Plessner Windish; Christopher B Fox; Steven G Reed
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

4.  Virus-activated interferon regulatory factor 7 upregulates expression of the interferon-regulated BST2 gene independently of interferon signaling.

Authors:  Mariana G Bego; Johanne Mercier; Eric A Cohen
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

Review 5.  Mucins and toll-like receptors: kith and kin in infection and cancer.

Authors:  Shikha Tarang; Sushil Kumar; Surinder K Batra
Journal:  Cancer Lett       Date:  2012-02-03       Impact factor: 8.679

Review 6.  Cellular stress response and innate immune signaling: integrating pathways in host defense and inflammation.

Authors:  Sujatha Muralidharan; Pranoti Mandrekar
Journal:  J Leukoc Biol       Date:  2013-08-29       Impact factor: 4.962

7.  TLR8-mediated activation of human monocytes inhibits TL1A expression.

Authors:  Masayuki Saruta; Kathrin S Michelsen; Lisa S Thomas; Qi T Yu; Carol J Landers; Stephan R Targan
Journal:  Eur J Immunol       Date:  2009-08       Impact factor: 5.532

8.  TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib.

Authors:  Adrian Wiestner; Sarah E M Herman; Eman L Dadashian; Erin M McAuley; Delong Liu; Arthur L Shaffer; Ryan M Young; Jessica R Iyer; Michael J Kruhlak; Louis M Staudt
Journal:  Cancer Res       Date:  2018-11-29       Impact factor: 12.701

9.  Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity.

Authors:  Nicole Asprodites; Liqin Zheng; Degui Geng; Cruz Velasco-Gonzalez; Luis Sanchez-Perez; Eduardo Davila
Journal:  FASEB J       Date:  2008-06-27       Impact factor: 5.191

10.  Immunological priming potentiates non-viral anti-inflammatory gene therapy treatment of neuropathic pain.

Authors:  E Sloane; S Langer; B Jekich; J Mahoney; T Hughes; M Frank; W Seibert; G Huberty; B Coats; J Harrison; D Klinman; S Poole; S Maier; K Johnson; R Chavez; L R Watkins; L Leinwand; E Milligan
Journal:  Gene Ther       Date:  2009-07-02       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.